Immuneering sets price for 6.3 million shares at $3.95 in private placement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 21 2025
0mins
Private Placement Agreement: Immuneering has entered into a definitive securities purchase agreement for a private placement expected to generate approximately $25 million in gross proceeds.
Details of the Offering: The agreement includes the sale of 6,329,113 unregistered shares of Class A common stock at $3.95 per share and warrants for an additional 2,848,096 shares at an exercise price of $5.50.
Pricing Information: The share price represents a 15% premium over the last reported closing price on August 20, 2025.
Investor Rights: Investors will receive registration rights, and the purchase warrants will be exercisable for five years after the shares are registered for resale.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMRX
Wall Street analysts forecast IMRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.060
Low
11.00
Averages
14.50
High
20.00
Current: 5.060
Low
11.00
Averages
14.50
High
20.00
About IMRX
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immuneering Reports Promising Phase 2a Data for Metastatic Pancreatic Cancer Treatment
- Clinical Trial Progress: Immuneering Corporation's Phase 2a trial for metastatic pancreatic cancer involved 56 patients treated with Atebimetinib in combination with mGnP, revealing a median overall survival of 17.3 months, indicating the drug's potential efficacy and offering new treatment options for patients.
- Adverse Event Monitoring: The only Grade-3 adverse events reported were anemia and neutropenia associated with chemotherapy, suggesting that Atebimetinib's safety profile is relatively manageable, laying a foundation for its future clinical applications.
- Future Research Plans: The company is currently recruiting patients for the Phase 3 MAPKeeper 301 trial, expecting to dose the first patient by mid-2026, demonstrating its ongoing commitment and investment in pancreatic cancer treatment research and development.
- Market Reaction: IMRX shares closed up 3.98% at $5.22 on Thursday, with after-hours trading rising 4.21% to $5.44, reflecting positive investor sentiment towards the clinical data, which may drive future funding and R&D advancements.
See More
Immuneering Reports Clinical Trial Data for Pancreatic Cancer
- Significant Survival Improvement: Immuneering reported a median overall survival of 17.3 months for first-line metastatic pancreatic cancer patients in its Phase 2a trial, indicating the drug's potential to extend patient life and possibly change treatment standards.
- Adverse Event Monitoring: Among treated patients, only 16% experienced anemia and 18% experienced neutropenia, both Grade 3 or higher treatment-related adverse events, suggesting good tolerability of the treatment regimen, which may attract more patients.
- ASCO Conference Presentation: The company will present complete data from 55 patients at the ASCO Annual Meeting on June 1, 2026, covering key metrics such as overall survival and progression-free survival, which is expected to garner significant attention from investors and the medical community.
- Follow-up Research Plans: Immuneering is currently recruiting patients for its pivotal Phase 3 MAPKeeper 301 clinical trial, aimed at further validating the efficacy of atebimetinib, demonstrating the company's ongoing commitment and strategic positioning in cancer treatment.
See More
Immuneering Q1 Earnings Beat Expectations
- Earnings Beat: Immuneering reported a Q1 GAAP EPS of -$0.21, exceeding market expectations by $0.04, indicating some resilience in financial performance despite ongoing losses.
- Cash Position Decline: As of March 31, 2026, the company's cash, cash equivalents, and marketable securities totaled $198.6 million, down from $217.0 million as of December 31, 2025, reflecting operational expenditure pressures.
- Optimistic Financial Guidance: Based on the cash position as of March 31, 2026, and current operational plans, the company expects its cash runway to be sufficient to fund operations into 2029, demonstrating confidence in financial management.
- Increased Market Attention: Following the earnings release, Immuneering's market attention has risen, with Seeking Alpha's Quant Rating expressing optimism about the company's future, potentially attracting more investor interest.
See More
Immuneering Reports New Data on Pancreatic Cancer Clinical Trials
- Clinical Trial Progress: Immuneering will present survival data from 55 first-line pancreatic cancer patients at the 2026 ASCO Annual Meeting, which is expected to further propel the clinical application of atebimetinib combined with mGnP, enhancing the company's market position in oncology.
- Key Trial Recruitment: The MAPKeeper 301 trial is now recruiting patients to evaluate the efficacy of atebimetinib with mGnP, with the first patient dosing expected to begin by mid-2026, marking a strategic move in the pancreatic cancer treatment landscape.
- Patient Survival Data: A third-line pancreatic cancer patient treated with atebimetinib monotherapy for 27 months has shown an 85% reduction in tumor burden, highlighting the drug's potential to extend survival and improve quality of life, which may provide critical insights for future treatment protocols.
- Strong Financial Position: As of Q1 2026, Immuneering reported $198.6 million in cash and cash equivalents, with an anticipated runway into 2029, demonstrating the company's ongoing investment capability in R&D and market expansion.
See More
Immuneering Presents Promising Data for Cancer Drug Atebimetinib
- Clinical Trial Data: Immuneering Corporation presented clinical trial data for its cancer drug Atebimetinib at the American Association of Cancer Research annual meeting, involving 123 patients, with 86 on monotherapy and 37 on combination therapy, indicating the drug's potential in anti-tumor activity.
- Resistance Mechanism Analysis: The data revealed that acquired mutations in tumor cells during treatment primarily occurred in non-MAPK pathways, suggesting that Atebimetinib may provide more durable effects in inhibiting tumor cell proliferation, potentially leading to longer survival for patients.
- Key Trial Progress: The company anticipates initiating the pivotal Phase 3 MAPKeeper 301 trial by mid-2026 to evaluate the efficacy of Atebimetinib combined with modified Gemcitabine/nab-Paclitaxel in treating first-line metastatic pancreatic cancer patients.
- Future Trial Plans: Immuneering also plans to begin a Phase 2 trial for Atebimetinib in the second half of this year, targeting first-line RAS-mutant non-small cell lung cancer patients, further validating its clinical application potential.
See More
Atebimetinib Shows Promising Results in Tumor Treatment
- Rare Resistance Mechanisms: Among 123 patients treated with atebimetinib, very few exhibited MAPK pathway mutations commonly associated with RAS inhibitors, indicating lower resistance in first-line treatment and enhancing its clinical application potential.
- Diverse Resistance Patterns: In 86 patients receiving monotherapy and 37 patients undergoing combination therapy, resistance mechanisms did not converge on the RAS/MAPK pathway but instead displayed a variety of non-MAPK pathways, showcasing atebimetinib's unique anti-tumor mechanisms.
- Limited Early Adaptive Resistance: ctDNA analysis revealed minimal early molecular evolution during treatment, suggesting that atebimetinib imposes less selective pressure, potentially improving treatment durability by reducing adaptive resistance.
- Clinical Trial Progress: Immuneering expects to initiate its pivotal MAPKeeper 301 Phase 3 trial in mid-2026, evaluating the efficacy of atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer, further validating its clinical value.
See More
Immuneering Reports Promising Phase 2a Data for Metastatic Pancreatic Cancer Treatment
- Clinical Trial Progress: Immuneering Corporation's Phase 2a trial for metastatic pancreatic cancer involved 56 patients treated with Atebimetinib in combination with mGnP, revealing a median overall survival of 17.3 months, indicating the drug's potential efficacy and offering new treatment options for patients.
- Adverse Event Monitoring: The only Grade-3 adverse events reported were anemia and neutropenia associated with chemotherapy, suggesting that Atebimetinib's safety profile is relatively manageable, laying a foundation for its future clinical applications.
- Future Research Plans: The company is currently recruiting patients for the Phase 3 MAPKeeper 301 trial, expecting to dose the first patient by mid-2026, demonstrating its ongoing commitment and investment in pancreatic cancer treatment research and development.
- Market Reaction: IMRX shares closed up 3.98% at $5.22 on Thursday, with after-hours trading rising 4.21% to $5.44, reflecting positive investor sentiment towards the clinical data, which may drive future funding and R&D advancements.
See More
Immuneering Reports Clinical Trial Data for Pancreatic Cancer
- Significant Survival Improvement: Immuneering reported a median overall survival of 17.3 months for first-line metastatic pancreatic cancer patients in its Phase 2a trial, indicating the drug's potential to extend patient life and possibly change treatment standards.
- Adverse Event Monitoring: Among treated patients, only 16% experienced anemia and 18% experienced neutropenia, both Grade 3 or higher treatment-related adverse events, suggesting good tolerability of the treatment regimen, which may attract more patients.
- ASCO Conference Presentation: The company will present complete data from 55 patients at the ASCO Annual Meeting on June 1, 2026, covering key metrics such as overall survival and progression-free survival, which is expected to garner significant attention from investors and the medical community.
- Follow-up Research Plans: Immuneering is currently recruiting patients for its pivotal Phase 3 MAPKeeper 301 clinical trial, aimed at further validating the efficacy of atebimetinib, demonstrating the company's ongoing commitment and strategic positioning in cancer treatment.
See More
Immuneering Q1 Earnings Beat Expectations
- Earnings Beat: Immuneering reported a Q1 GAAP EPS of -$0.21, exceeding market expectations by $0.04, indicating some resilience in financial performance despite ongoing losses.
- Cash Position Decline: As of March 31, 2026, the company's cash, cash equivalents, and marketable securities totaled $198.6 million, down from $217.0 million as of December 31, 2025, reflecting operational expenditure pressures.
- Optimistic Financial Guidance: Based on the cash position as of March 31, 2026, and current operational plans, the company expects its cash runway to be sufficient to fund operations into 2029, demonstrating confidence in financial management.
- Increased Market Attention: Following the earnings release, Immuneering's market attention has risen, with Seeking Alpha's Quant Rating expressing optimism about the company's future, potentially attracting more investor interest.
See More
Immuneering Reports New Data on Pancreatic Cancer Clinical Trials
- Clinical Trial Progress: Immuneering will present survival data from 55 first-line pancreatic cancer patients at the 2026 ASCO Annual Meeting, which is expected to further propel the clinical application of atebimetinib combined with mGnP, enhancing the company's market position in oncology.
- Key Trial Recruitment: The MAPKeeper 301 trial is now recruiting patients to evaluate the efficacy of atebimetinib with mGnP, with the first patient dosing expected to begin by mid-2026, marking a strategic move in the pancreatic cancer treatment landscape.
- Patient Survival Data: A third-line pancreatic cancer patient treated with atebimetinib monotherapy for 27 months has shown an 85% reduction in tumor burden, highlighting the drug's potential to extend survival and improve quality of life, which may provide critical insights for future treatment protocols.
- Strong Financial Position: As of Q1 2026, Immuneering reported $198.6 million in cash and cash equivalents, with an anticipated runway into 2029, demonstrating the company's ongoing investment capability in R&D and market expansion.
See More
Immuneering Presents Promising Data for Cancer Drug Atebimetinib
- Clinical Trial Data: Immuneering Corporation presented clinical trial data for its cancer drug Atebimetinib at the American Association of Cancer Research annual meeting, involving 123 patients, with 86 on monotherapy and 37 on combination therapy, indicating the drug's potential in anti-tumor activity.
- Resistance Mechanism Analysis: The data revealed that acquired mutations in tumor cells during treatment primarily occurred in non-MAPK pathways, suggesting that Atebimetinib may provide more durable effects in inhibiting tumor cell proliferation, potentially leading to longer survival for patients.
- Key Trial Progress: The company anticipates initiating the pivotal Phase 3 MAPKeeper 301 trial by mid-2026 to evaluate the efficacy of Atebimetinib combined with modified Gemcitabine/nab-Paclitaxel in treating first-line metastatic pancreatic cancer patients.
- Future Trial Plans: Immuneering also plans to begin a Phase 2 trial for Atebimetinib in the second half of this year, targeting first-line RAS-mutant non-small cell lung cancer patients, further validating its clinical application potential.
See More
Atebimetinib Shows Promising Results in Tumor Treatment
- Rare Resistance Mechanisms: Among 123 patients treated with atebimetinib, very few exhibited MAPK pathway mutations commonly associated with RAS inhibitors, indicating lower resistance in first-line treatment and enhancing its clinical application potential.
- Diverse Resistance Patterns: In 86 patients receiving monotherapy and 37 patients undergoing combination therapy, resistance mechanisms did not converge on the RAS/MAPK pathway but instead displayed a variety of non-MAPK pathways, showcasing atebimetinib's unique anti-tumor mechanisms.
- Limited Early Adaptive Resistance: ctDNA analysis revealed minimal early molecular evolution during treatment, suggesting that atebimetinib imposes less selective pressure, potentially improving treatment durability by reducing adaptive resistance.
- Clinical Trial Progress: Immuneering expects to initiate its pivotal MAPKeeper 301 Phase 3 trial in mid-2026, evaluating the efficacy of atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer, further validating its clinical value.
See More
